Trial Tuesday! Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026

Promising results for stage III lung cancer: The AFT 46/CHIO3 trial study show combining immunotherapy and chemotherapy before surgery improves outcomes for against with locally advanced non-small cell lung cancer. Dana-Farber Cancer Institute #LCSM https://bit.ly/AFT46

Congratulations to Alliance researchers presenting at #AACR2026. Highlights include advancing early phase trial design, uncovering AML mutations tied to survival, and showing that healthy lifestyle can improve colon cancer outcomes during chemo. Proud of their work! https://bit.ly/AACR-Alliance26

April is #HeadAndNeckCancerAwarenessMonth. This includes cancers in the larynx, throat, lips, mouth, nose, and salivary glands. Learn more about symptoms, prevention, & screening resources on the NCI’s website: https://ow.ly/AiqN50VrKPw

April is #HeadAndNeckCancerAwarenessMonth 🧡
The Alliance for Clinical Trials in Oncology has multiple clinical trials open for patients facing head and neck cancers—focused on improving outcomes and quality of life. Learn more: https://bit.ly/HN-2026 #HeadAndNeckCancer

Now recruiting! Dr. Bradley McGregor of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A032201-STRIKE to see if adding the tivozanib to the standard immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201

#AACR26 Come to my poster (Section #35 Poster #11) on 4/21 (Tuesday) 9AM-12PM PST @theaacr.bsky.social!

Using Alliance data (CALGB/SWOG 80702), I will present the findings how adhering to WCRF/AICR Recommendations may improve colon cancer survival and impact chemotherapy outcomes.

Congratulations to Alliance researchers presenting at #AACR2026. Highlights include advancing early phase trial design, uncovering novel AML mutations tied to survival, and showing that healthy lifestyle adherence improves colon cancer outcomes during chemo. Proud of their work!

Now enrolling! Drs. Rana McKay of UC San Diego Health Sciences and Misha Beltran of Dana-Farber Cancer Institute lead Alliance for Clinical Trials in Oncology A032102/PREDICT testing if genetic testing helps find the best treatments for metastatic prostate cancer. https://bit.ly/Alliance-A032102

Sara Tolaney of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A012103 for early-stage breast cancer patients with complete response after chemo + pembrolizumab. This trial compares continuing pembrolizumab vs monitoring after surgery. https://bit.ly/Alliance-A012103

Drs. Thomas Hope of UCSF Helen Diller Family Comprehensive Cancer Center and Deaglan McHugh of Memorial Sloan Kettering Cancer Center lead A032304 (RECIPROCAL) studying if targeted radiation can minimize side effects while preserving efficacy in prostate cancer. https://bit.ly/AllianceA032304

Trial Tuesday! The Alliance has a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma. Visit https://bit.ly/CLL-SLL to learn about Alliance A042302 led by Dr. Jennifer R. Brown of Dana-Farber Cancer Institute

A new trial is tackling a common but overlooked side effect of breast cancer treatment. The #REVITALIZE study is testing laser therapy to relieve chronic vaginal dryness and improve quality of life for survivors. https://bit.ly/REVITALIZE2026 💗 Tufts University School of Medicine Yale Cancer Center

A new trial is tackling a common but overlooked side effect of breast cancer treatment. The #REVITALIZE study is testing laser therapy to relieve chronic vaginal dryness and improve quality of life for survivors. 💗🧪 Tufts University School of Medicine Yale Cancer Center #BCSM #womenshealth

Dr. Haeseong Park of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A022102 studying mFOLFIRINOX vs. mFOLFOX with or without immunotherapy for metastatic HER2 negative esophageal, gastroesophageal junction and gastric cancer. Learn more: https://bit.ly/Alliance-A022102

NRG/Alliance LU005 results in the Journal of Clinical Oncology show immunotherapy given during and after chemoradiation does not improve survival for small-cell lung cancer, but twice daily radiation may. https://bit.ly/SCLC-Mar2026 https://bit.ly/LU005-JCO American Society of Clinical Oncology

Now enrolling! The phase III HOPE study (A222301) led by Anurag Singh, MD of Roswell Park Comprehensive Cancer Center is assessing if high-dose gabapentin reduces opioid use in patients with oral mucositis during chemoradiation for head and neck cancer. Learn more: https://bit.ly/Alliance-A222301

New publication alert! Landmark Alliance ATOMIC trial in NEJM.org establishes news standard of care for patients with dMMR #coloncancer. Learn more, visit https://bit.ly/ATOMIC2026 and https://bit.ly/ATOMIC-NEJM #ATOMIC #NCI #NCTN #CancerResearch #CRCsm Mayo Clinic

Publication alert! A randomized trial led by Dr. Ellen Smith of University of the Alabama Birmingham in JCO Oncology Advances shows duloxetine, a common anti-depressant, does not prevent nerve damage caused by chemotherapy. https://bit.ly/NeuropathyPain https://bit.ly/JCO-Advances

Now enrolling! Dr. Bhavana Konda of Ohio State leads Alliance for Clinical Trials in Oncology A092204 exploring if using two targeted drugs help slow tumor growth in #AYA adrenocortical carcinoma, a rare cancer of the adrenal glands. https://bit.ly/A092204-Konda #NCI #AYAWeek #AYACancerAwareness

Trial Tuesday! Dr. Deepak Kilari from Medical College of Wisconsin is now enrolling Alliance for Clinical Trials in Oncology A032302 (ASPIRE) to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. Learn more at http://bit.ly/AllianceA032302

Now enrolling! Angela Bradbury MD Penn Medicine - Abramson Cancer Center leads Alliance
A232301CD seeing if digital chatbot is as effective as standard genetic services in increasing counseling uptake among #AYA #cancer patients https://bit.ly/AllianceA232301CD #AYAWeek #AYACancerAwareness

New trial! With colorectal cancer, if a person has a gene change, other family members are at risk. A new trial will evaluate if more people will get genetic testing if they hear about inherited cancer risks from a health provider. More at https://bit.ly/CRCGene-Testing #AYAWeek #AYACancerAwareness

Did you know adolescents and young adults (#AYA, ages 15 to 39) represent 4% of all cancers diagnosed each year. They can be treated pediatric or adult centers, but often feel they don’t fit into either category. More info https://bit.ly/AYA2026 #AYAWeek #AYACancerAwareness

The Alliance is more than finding new and better ways to cure cancer; we also work to prevent it. The Alliance has three active trials focusing on lowering the chances of cancer developing in the first place. More at https://bit.ly/Prevent26

Missed Alliance’s Best of ASH and SABCS webinar? It’s now available online. Learn from investigators about new advances impacting treatments for breast cancer, multiple myeloma and leukemia. https://bit.ly/AllianceWebinar2026 #ASH25 #SABCS25

Now enrolling! Dr. Gabriel Brooks of Dartmouth Cancer leads the PAGODA trial (Alliance A232402CD) aimed to reduce unplanned treatment delays in people with gastrointestinal cancers. Learn more at https://bit.ly/PAGODA26 #colorectalcancer

At the Alliance for Clinical Trials in Oncology, we share stories that highlight the progress and impact of cancer research. Click to see some of our recent media coverage.
bit.ly/MarchMedia2026

🚨 New research from Alliance A222001 by Dr. Bradley Stish at Mayo Clinic shows oxybutynin reduces hot flashes in men undergoing hormone therapy for prostate cancer. Findings in Journal of Clinical Oncology The ASCO Post More at https://bit.ly/Stish-JCO and https://bit.ly/JCOarticle-Stish

Dr. Eric Miller of The Ohio State University Wexner Medical Center and Dr. Sepideh Gholami of Northwell Health presented at #SSO2026 on A022101/NRG-GI009 (ERAsur) testing if adding radiation to chemo improves outcomes for colorectal cancer #ColorectalCancer https://bit.ly/SSO-2026